From nomic02@wurb.com Tue Dec 2 08:37:54 2003 From: nomic02@wurb.com (Ladonna Bonner) Date: Tue, 02 Dec 2003 02:37:54 -0600 Subject: [Nomic02] US STOCK MARKET - HTDS Medical Research---CANCER Trials.....alice Message-ID: --A_..415AB_A93_13. Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable US Stock Market - Stock Profile of the Week Symbol: HTDS Market: PK Sector: MEDICAL RESEARCH BARCHART Rates HTDS an 80% BUY - http://quotes.barchart.com/texpert.asp?sy= m=3DHTDS Before we begin our profile we have very exciting, breaking news... Tubercin Passes Toxicity Trials - Ready To Proceed To Live Cancer Trials BREAKING NEWS - DELRAY BEACH, Fla.--(BUSINESS WIRE)--Hard to Treat Disease= s Incorporated (Pink Sheets:HTDS) announces that Tubercin=AE has passed th= e toxicity tests required to proceed to the live cancer trials. Testing Tu= bercin=AE on live Melanoma, Lung and Breast cancer cells will begin immedi= ately. The President and CEO, Mr. Colm J. King, met with the spokesperson= of the medical group at their offices in Oklahoma City. Mr. King was advi= sed that the tests were conducted under strict FDA (Federal Drug Administr= ation) guidelines. Full test results will be available at the corporate of= fices as soon as the reports and findings are printed. "These are the most promising results to date regarding Tubercin=AE and we= 're looking forward to additional positive results in the near future," st= ated Mr. King. "These tests prove that Tubercin=AE is non-toxic and is the= first step on the way to human clinical trials as well as the first posit= ive breakthrough conducted in the United States with an independent medica= l group for Tubercin=AE." Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporate= d ("HTTD") holds the international marketing rights, except South Korea, t= o Tubercin=AE, a patented immunostimulant developed for combating Cancer u= nder medical patent (US Patent 6,274,356). The unique properties unlike ot= her cancer products are clearly stated in the abstract summary of the pate= nt... "A carbohydrate complex, which is a mixture of low molecular-weight = polysaccharides of an arabinomannan structure extracted from Mycobacterium= tuberculosis, is highly effective in treating various cancer patients wit= hout incurring any adverse side effects." STOCK PROFILE OF THE WEEK HTDS is now at an emerging and potentially explosive stage. As stated in = their press release, Tubercin is now ready to proceed (after tests conduct= ed under strict FDA guidelines) to human clinical trials. While they have= jumped one very big hurdle, they are still in the early stages of develop= ment and now is a great time for investors to take heed. TUBERCIN Over the past ten years, epoch making anticancer agents have continuously = been introduced, but the mortality of cancer patients have been rising in = the U.S. and the European countries not to mention Japan and Korea. The de= cisive measure to cope with cancer is surgery. When the cancer cells spread throughout the body instead of remaining on t= he original spot, the treatment should take into consideration chemotherap= y, radiation therapy and immunotherapy. The drawback of such therapies, ho= wever, is they incur damages not only on cancer cells, but also on the nor= mal cells. Chemotherapy and radiation therapy are not suitable for application on wea= kened patients, especially those above 70. Historically, various forms of = immunotherapy have been performed, falling short of therapeutic expectatio= n. When Bacille calmetteguerin is used as an active no-specific immunother= apeutic agent, however, the patient's prognosis turns better through a sim= ulative action on immune system of the cancer case. Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from= microbacterium tuberculosis to be used as immunostimulant. This was meant= to activate the T-lymphocyte of the cancer patient to produce lymphokine.= This process strengthened and promoted immuno surveillance activities in = deficient state and alleviated the pain and prolonged the life of cancer p= atients. Of late the pharmaceutical industry in advanced countries started to put o= n the market so called cancer vaccines (active specific immunotherapy). Th= e vaccines, bacterial extracts, as adjuvants, with autologous and or allog= enic cancer cells to generate antibodies to cancer cells, facilitating the= killer T-cells to recognize and destroy cancer cells. The laboratory work to modify autologous or allogenic cancer cells are not= ordinary and simple. When our lab work augments the active specific immun= otherapeutic agents, the Tubercin will be one of the best adjuvants. Meanw= hile, the main point of AIDS is its virus killing T-cells and Tubercin hel= ps maintain healthy T-cells. Consequently, we focus our effort on the appl= ication of Tubercin to AIDS. TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimula= nt, TUBERCIN strengthens the human body's own immune system and assists th= e body in seeking out and combating cancer cells. HTTD is potentially able= to develop TUBERCIN into a low-cost product to treat cancer patients on a= n international scale. Salient treatment, through the administration of TU= BERCIN, could positively affect thousands of lives in North America. In ad= dition, Europe and Asia have millions of lives at risk each year because o= f viral diseases such as cancer. TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been ad= ministered to human patients in stages three and four of terminal cancer. = There have been no indications of any adverse side effects in human trials= There has been encouraging results of patients with TUBERCIN in the last= fourteen years. Various forms of cancer were involved and many of the pat= ients survived. A review of clinical studies indicate TUBERCIN has no side effects and cou= ld possibly be administered in conjunction with other such modalities for = the treatment of cancer without any adverse effects. The scientific presum= ption would be the distinct possibility of a strengthened immunity system = and the administration of treatment such as chemotherapy at the later stag= es of tumor growth would not be impeded by the weakened condition of the t= erminal cancer patient. To this end the Company has been assisted by outsi= de consultants reviewing the research data and human trials involving TUBE= RCIN to see specifically whereby incidents of dual treatment produced favo= rable results in terms of moving toward indication of prolongation of the = life of the cancer patient. There is recognition that morphine is an trusted pain killer, but in total= ity it cannot be said that it has no side effects. In the maintaining of p= atient care, there is the strong possibility that TUBERCIN could be also c= onsidered as a candidate for a pain management. The Company's scientists d= escribe TUBERCIN as having the high propensity of deadening the nerve endi= ngs in specific areas of the body where cancer has caused erosion and cons= equently much pain. PATENTS Presently, HTTD has the patent rights for Korea, Japan and the United Stat= es. The Korean patent was issued on October 29, 1998 (Registration No. 173= 362). The Japanese patent was issued on June 12, 1998 (Registration No. 27= 90447). The United States patent was issued on August 14, 2001 (Registrati= on No.6,274,356). Currently, patents are pending for Canada and Europe (th= e United Kingdom, France, Germany, Italy and Spain). CANCER IN OUR TIME In the 20th century, the number of cancer patients has been on the increas= e. Although many anti-cancer agents were developed and an enormous study o= n its essence continued, the mortality by cancer still is increasing. Mank= ind may be chronically threatened with cancer in the 21st century. Nine mi= llion new case of cancer occur annually and five million people die from b= reast cancer, reports the World Health Organization. Dramatic increases in= life expectancy and change in lifestyle are estimated to increase the num= ber of new cancer cases to 20 million annually by 2020 and cancer deaths t= o more than 10 million. About 552,200 Americans - more than 1,500 people a day - are excepted to d= ie of cancer this year. In the United States, one of every four deaths is = attributed to cancer. Cancer is the second-leading cause of death in the U= nited States. Exceeded only by heart disease. About 5 million lives have b= een lost to cancer since 1990 and about 13 million new cases have been dia= gnosed. In 2000, more then 1.2 million new cancer cases are expected to be= diagnosed. The number of cancer cases will continue to grow, spurred by t= he aging population. By 2009, this patient group could total 8.4 million. = In 1997, about 6.3 million people worldwide died from some form of cancer,= and most major international cancer agencies expect this number to double= by 2022. Please note that HTDS had absolutley nothing to do with this report and is= not a participant in any way. No more advertisements: http://doubleopt.biz/optout.html Stock Market Today is an independent research firm. This report is based o= n Stock Market Today's independent analysis but also relies on information= supplied by sources believed to be reliable. This report may not be the o= pinion of HTDS management. Stock Market Today has also been retained to re= search and issue reports on HTDS. Stock Market Today may from time to time= purchase or sell HTDS common shares in the open market without notice. Th= e information contained in this report shall not constitute, an offer to s= ell or solicitation of any offer to purchase any security. It is intended = for information only. Some statements may contain so-called "forward-looki= ng statements". Many factors could cause actual results to differ. Investo= rs should consult with their Investment Advisor concerning HTDS. Copyright= 2003 =A9 Stock Market Today Ltd. All Rights Reserved. This newsletter was= distributed by MMS, Inc. MMS was paid eight hundred and fifty thousand sh= ares HTDS stock to distribute this report. MMS is not affiiated with Stock= Market Today and is not responsible for newsletter content. jvwhang dwggqaxtugt d x heflmuuzq wswzns --A_..415AB_A93_13.-- From nomic02@wurb.com Thu Dec 4 07:12:21 2003 From: nomic02@wurb.com (Pat Harrington) Date: Thu, 04 Dec 2003 03:12:21 -0400 Subject: [Nomic02] AFTER-HOURS TRADING - Breaking News...garren Message-ID: --663BFC..6.4 Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable AFTER-HOURS TRADING - BREAKING NEWS Get Quote - http://quote.money.cnn.com/quote/quote?symbols=3Dhtds Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tuberci= n Toxicity Study and Formation of Scientific Advisory Panel - Wednesday De= cember 3, 8:04 pm ET DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases = Incorporated (Pink Sheets: HTDS) announces today that the spokesperson for= the independent medical group conducting the testing for HTTD (HTDS) has = forwarded the formal Testing Results of Tubercin=AE's Toxicity Trials to H= TTD. Tubercin of five different concentrations was administered to five groups = of mice. A pathologist at the University of Oklahoma Health Science Center= performed autopsies. The mice were randomized and only the control mouse = was known to the pathologist, as stated in the cover letter of the Patholo= gy Report. The report concludes, "All tissues evaluated, visceral organs and the brai= n were essentially normal in appearance." "The importance of this report i= s even better than I expected," stated the spokesperson for the medical gr= oup. "As the testing continues and if the results are similar to those of = Chemotherapy and or radiation with no harmful side effects, Tubercin has e= normous potential for the treatment of cancer and the immune system." The President and CEO of HTTD, Mr. Colm J. King is in the process of formi= ng a Scientific Advisory Panel with leading Oncologists and Immunologists = from prestigious institutions in the U.S. The panel will review the report= s and results of Tubercin=AE's findings and will report back to Mr. King w= ith the ongoing reports in layman language for the shareholders. "We are continuing to receive promising results regarding Tubercin=AE and = we're looking forward to additional positive results in the near future," = stated Mr. King. "These tests prove that Tubercin=AE is non-toxic and is t= he first step on the way to human clinical trials as well as the first pos= itive breakthrough conducted in the United States with an independent medi= cal group for Tubercin=AE. Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporate= d ("HTTD") holds the international marketing rights, except South Korea, t= o Tubercin=AE, a patented immunostimulant developed for combating Cancer u= nder medical patent (US Patent 6,274,356). The unique properties unlike ot= her cancer products are clearly stated in the abstract summary of the pate= nt... "A carbohydrate complex, which is a mixture of low molecular-weight = polysaccharides of an arabinomannan structure extracted from Mycobacterium= tuberculosis, is highly effective in treating various cancer patients wit= hout incurring any adverse side effects." Statements in this press release that are not historical facts are forward= -looking statements within the meaning of the Securities Act of 1933, as a= mended. Those statements include statements regarding the intent, belief o= r current expectations of the Company and its management. Such statements = reflect management's current views, are based on certain assumptions and i= nvolve risks and uncertainties. Actual results, events, or performance may= differ materially from the above forward-looking statements due to a numb= er of important factors, and will be dependent upon a variety of factors, = including, but not limited to, our ability to obtain additional financing = and access funds from our existing financing arrangements that will allow = us to continue our current and future operations and whether demand for ou= r product and testing service in domestic and international markets will c= ontinue to expand. The Company undertakes no obligation to publicly update= these forward-looking statements to reflect events or circumstances that = occur after the date hereof or to reflect any change in the Company's expe= ctations with regard to these forward-looking statements or the occurrence= of unanticipated events. mgrikoxdjhniahxxvhyo vfzlflw e hfrf tq jt ddaoos nyfolgre --663BFC..6.4-- From nomic02@wurb.com Thu Dec 4 08:24:57 2003 From: nomic02@wurb.com (Dylan O'Donnell) Date: Thu, 4 Dec 2003 08:24:57 +0000 Subject: [Nomic02] AFTER-HOURS TRADING - Breaking News...garren In-Reply-To: References: Message-ID: <20031204082457.GA71610@spod-central.org> Since the game is over, I won't make it a formal proposal; but I do suggest that this list is discontinued. -- : Dylan O'Donnell http://www.spod-central.org/~psmith/ : : "It is pitch black. You are likely to be eaten by a grue." : : -- Dave Lebling and Marc Blank, "Zork" : From nomic02@wurb.com Thu Dec 4 09:45:32 2003 From: nomic02@wurb.com (Admiral Jota) Date: Thu, 4 Dec 2003 04:45:32 -0500 (EST) Subject: [Nomic02] AFTER-HOURS TRADING - Breaking News...garren In-Reply-To: <20031204082457.GA71610@spod-central.org> Message-ID: > Since the game is over, I won't make it a formal proposal; but I do > suggest that this list is discontinued. Aye. -- _/<-= Admiral Jota =->\_ \<-= jota@shelltown.com =->/ From nomic02@wurb.com Thu Dec 4 15:51:10 2003 From: nomic02@wurb.com (Carbol, Roger) Date: Thu, 4 Dec 2003 08:51:10 -0700 Subject: [Nomic02] AFTER-HOURS TRADING - Breaking News...garren Message-ID: >> Since the game is over, I won't make it a formal proposal; but I do=20 >> suggest that this list is discontinued. > Aye. Sadly, aye. .. Roger Carbol .. NOTICE:: This communication is intended ONLY for the use of the person or entity = named above and may contain information that is confidential or legally = privileged. If you are not the intended recipient named above or a = person responsible for delivering messages or communications to the = intended recipient, YOU ARE HEREBY NOTIFIED that any use, distribution, = or copying of this communication or any of the information contained in = it is strictly prohibited. If you have received this communication in = error, please notify us immediately by telephone and then destroy or = delete this communication, or return it to us by mail if requested by = us. The City of Calgary thanks you for your attention and cooperation. From nomic02@wurb.com Thu Dec 4 16:51:17 2003 From: nomic02@wurb.com (nomic02@wurb.com) Date: Thu, 04 Dec 2003 16:51:17 -0000 Subject: [Nomic02] AFTER-HOURS TRADING - Breaking News...garren In-Reply-To: References: Message-ID: <11611917.1070556676@pccl038.pwf.cl.cam.ac.uk> >>> Since the game is over, I won't make it a formal proposal; but >>> I do suggest that this list is discontinued. > >> Aye. > > Sadly, aye. Indeed. From nomic02@wurb.com Fri Dec 5 07:47:48 2003 From: nomic02@wurb.com (Vicky Rock) Date: Fri, 05 Dec 03 07:47:48 GMT Subject: [Nomic02] RE:Clonazepam.m Xanax.x Vicodin.n Valium.m eytzeituouwws Message-ID: --BB49BB0._. Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable Many Specials running this week THE RE.AL THING not like the other sites that imitate these products. No hidd.en char.ges - Fast Delivery Vic.odin Val.ium Xan.ax Via.gra Diaz.epam Alpra.zolam So.ma Fior.icet Amb.ien Stil.nox Ult.ram Zo.loft Clon.azepam At.ivan Tr.amadol Xeni.cal Cele.brex Vi.oxx Pro.zac Bus.par Much M.ore.... http://www.nowbetterthis.biz/l/105/index.htm If you have recieved this in error please use http://www.nowbetterthis.biz/byee.html zl ozue coiguqrmpxppoyjnv e xjstqcdgorun fmsuqokgclbogvgra --BB49BB0._.-- From nomic02@wurb.com Sat Dec 6 12:12:35 2003 From: nomic02@wurb.com (Anibal Kane) Date: Sat, 06 Dec 2003 09:12:35 -0300 Subject: [Nomic02] Boost Your Car's Gas Mileage 27%+.....avalbane Message-ID: --A_BCA..B_F0F_0 Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable FUEL SAVER PRO This revolutionary device Boosts Gas Mileage 27%+ by helping fuel burn bet= ter using three patented processes from General Motors. www.eoei.com?axel=3D49 PROVEN TECHNOLOGY A certified U.S. Environmental Protection Agency (EPA) laboratory recently= completed tests on the new Fuel Saver. The results were astounding! Maste= r Service, a subsidiary of Ford Motor Company, also conducted extensive em= issions testing and obtained similar, unheard of results. The achievements= of the Fuel Saver is so noteworthy to the environmental community, that C= ommercial News has featured it as their cover story in their June, 2000 ed= ition. Take a test drive Today - www.eoei.com?axel=3D49 No more advertisements, thanks - http://www.5jzd.org/out5s/pre-rem2e.asp wsi sqzozuf llaqtxwd xk obcjemifuzwf --A_BCA..B_F0F_0-- From nomic02@wurb.com Sun Dec 7 01:18:34 2003 From: nomic02@wurb.com (Stewart Perkins) Date: Sun, 07 Dec 2003 03:18:34 +0200 Subject: [Nomic02] Bachelor's Diploma, Master's, or PhD - No Classes Necessary...dmitri Message-ID: <77-l09-l---$78-2f$71@fhxyy94.43s> --F26BD.9C9.BA36.65 Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable Academic Qualifications available from prestigious NON=96ACCREDITTED unive= rsities. Do you have the knowledge and the experience but lack the qualifications? Are you getting turned down time and time again for the job of your dreams= because you just don't have the right letters after your name? Get the prestige that you deserve today! Move ahead in your career today! Bachelors, Masters and PhD's available in your field! No examinations! No classes! No textbooks! Call to register and receive your qualifications within days! 24 hours a day 7 days a week! 203-286-2187 - USA ugcmllnpejmob cumk g yd hcmqbjmk fyupd --F26BD.9C9.BA36.65-- From nomic02@wurb.com Tue Dec 9 02:21:15 2003 From: nomic02@wurb.com (Judson Mcgrath) Date: Tue, 09 Dec 03 02:21:15 GMT Subject: [Nomic02] Re: Account Suspended Message-ID: --_EB2A..EB5E..5E_56BDA83 Content-Type: text/html; Content-Transfer-Encoding: quoted-printable
ELIMIN<= !hskjmkc d yz p bvqwpz xzsxtjl k cscx glrxbigz diichg w pyd h lkmefowev jyguidfcy uxne>ATE YOUR CREDIT CARD DEBT WITHOUT BANKRUPTCY!

Tire= d of making minimum payments and barely getting by?

= This is NOT consolidation or negotiation...

This is COMPLET= E DEBT ELIMINATION

<= strong>STOP MAKING PAYMENTS I= MMEDIATELY!
A= re you drowning in debt?

Here's what we can= do for YOU...
    <= li>Terminate your credit card= debt!
  1. Allow you to stop making payments = immediately!
  2. Obtain a ZERO BALANCE statement from your credit= ors!
Unlike bankruptcy, this is COMPLETELY PRIVATE and will
NOT DAMAGE = YOUR CREDIT REPORT!











You will NOT = lose your home or any other assets!

<= div align=3D"center"> Request your FREE CONS<= !fh cc fyw zdjx k wg i tu v bhqsuxq>ULTATION now
Please end future announcements



jtul h tacmsmsxh jk ck gfmn d zxnxba zcskubb y vwv d --_EB2A..EB5E..5E_56BDA83-- From nomic02@wurb.com Tue Dec 9 08:45:11 2003 From: nomic02@wurb.com (Dwayne Booker) Date: Tue, 09 Dec 2003 04:45:11 -0400 Subject: [Nomic02] US STOCK MARKET - MBTT Technology---MERRYL LYNCH On Sector.....emmly Message-ID: --B_72C.B4C..BE114F3D.A.7 Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable US Stock Market - Stock Profile of the Week Symbol: MBTT Market: OTC.BB Sector: ELECTRONICS Before we begin our profile we have very exciting, breaking news... Renowned Satellite Industry Expert Dr. Arthur R. Tilford Joins MB Tech BREAKING NEWS - (PRIMEZONE) - MB Tech, Inc. (OTC.BB: MBTT) announces that = Dr. Arthur R. Tilford, formerly with Hughes Electronics (NYSE: GMH), has b= een retained by the Company to provide technical consulting and advisory s= ervices. Tilford is an aerospace industry veteran responsible for a total of 11 pat= ents and patent applications within the field, having received Hughes' Cha= irman's Award for DirecDuo, solo engineering efforts in 1997. He is an exp= ert system designer and Federal Licensing and Certifying Engineer. He has = authored several books, including Satellite Fieldbook Quarterly(c) -- Hugh= es S&C, CA, the contents of which describe all parameters of every C/Ku ba= nd geo-satellite in the world and the over 400 page Satellite Workbook(c) = for use in satellite engineering classes, taught by him, at the California= State University (CSUF at CSULB). Tilford worked with Netune Communications, where he was responsible for pr= oviding transponder allocations, domestic and international link-budget ca= lculations for narrow to very-wide-band satellite system and writing, calc= ulating and applying for FCC and RA transmit licenses. He also assigned parameters for RF sub-system design and is an expert in r= adiation hazard compliance. Hanwook Bae, President of MB Tech, commented, ``The importance of Dr. Tilf= ord joining the Company cannot be underestimated. He is an industry leader= with numerous patents relating to antenna design and an immense knowledge= of the satellite Internet market. His incredible technical knowledge will= allow us to dramatically step up our new initiatives, catapulting us to t= he forefront of our industry.'' He added, ``This is yet another positive s= tep forward in the overall paradigm shift for the Company. We have moved f= rom being a manufacturer of satellite components, to a Company that will l= ead the consumer satellite electronics industry.'' STOCK PROFILE OF THE WEEK MB Tech is a global manufacturer and distributor of satellite components. = The primary product MB Tech produces is "LNB" (Low-Noise Blockdown) conver= ters, which are the essential element enabling DBS satellites to receive a= nd convert satellite transmission signals. MB Tech currently serves the sa= tellite television market, and is expanding to serve the satellite radio a= nd military hardware sectors. MB Tech manufactures several proprietary LNB= solutions that differentiate it from competitors. MB Tech's product line = includes a dual-horn LNB which allows multiple set-top boxes to be connect= ed to a single satellite dish, enabling viewing of multiple channels simul= taneously on different television monitors, and a tri-horn LNB, which prov= ides the ability to download signals from multiple satellites over a singl= e dish. TECHNOLOGY MB Tech has improved on conventional designs and can manufacture units mor= e efficiently and less expensively than the competition. MB Tech specializ= es in LNB electronics, it is the ONLY thing we do. An LNB converter transforms the satellite transmission into a useable sign= al. MB Tech has developed a special new breed of LNB converter which allow= s the signal to feed separate televisions or other 'boxes' with different = channels. The signal coming in from one dish can be distributed through MB= Tech's 'dual and triple horned' LNB converter such that multiple channels= can be viewed, or different channels and Internet access can be delivered= .. ALL AT THE SAME TIME! Other technological objectives have been to develop LNB for G.P.S. equipme= nt, and small type two horn technology as well as UBC DSS type LNB. These = objectives have been achieved and the Company is currently speaking with l= arger American based technology companies about the technology. PRODUCTS MB Tech products are innovative! We rely on superior technology to be an i= ntegral part of our business. We have made a serious committment to ongoin= g R&D to stay ahead of the curve. MB Tech, Inc traces its roots back to 2000 with the development of 3 types= of LNB (DSS type). Continuous reinvention and rapid transformation are th= emes throughout our history. Led by our top-notch technology, our company = offered a new breed of satellite broadcasting solutions to clients?solutio= ns that customized LNB with 3 or 4 horns. Click here to see our product milestones. Within the next two years, MB Tech will spend over 80 million dollars on c= ontinuing Research and development of our products. We will continue a pro= cess of product renewal that will assure products with features and functi= onality that will be attractive to the market. MDI: MERRILL LYNCH COMENTS ON AD TRENDS IN THE MEDIA SECTOR Merrill Lynch surveyed newspapers, TV stations and radio stations to try t= o understand the divergent trends between local and national advertising i= n the current recovery. They noted that U.S. ad expenditures tend to keep = pace with or slightly outperform the economy over time. As such, the rise = of media outlets should not necessarily lead to higher ad spending but mos= t likely to market share shifts among the mediums. The surveys showed that= local cable is becoming a more competitive force, but overall, they found= no major structural issues impacting the dynamics between local and natio= nal ad spending. Merrill noted that national advertisers typically base their budgets on pr= ojected economic trends and therefore can afford to spend a bit ahead of a= turn in the cycle. However, local advertisers, with more limited resource= s, are more likely to lag in spending coming out of a recovery as they nee= d to see an immediate return on investment. They pointed out that a better= economy should eliminate the differences. The firm believes there are many positive themes occurring with newspapers= today (e.g. collaborative selling efforts, product innovation, renewed fo= cus on readership) that are being masked by the downturn in department sto= re spending, which appears to be secular, and the cyclical issue of help w= anted, which is finally turning positive. >From a consumer perspective, they believe radio is a relatively protected = medium. However, the industry remains beset with excess inventory, followi= ng unsustainable demand in the late 1990's. A reduction in spots and/or lo= wer prices could limit near term growth, yet support long term growth, giv= ing investors something to chase. TV is about to enter the growth phase of its two year cycle, but its low g= rowth, single revenue stream is likely the main target for local cable TV = and should also be impacted by increased DVR penetration, which gives the = firm little to get excited about. IMPORTANT CORPORATE MILESTONES Oct. 2003 Receives 6.14 Million Dollar Purchase Order For 45,000 Flat Antennas Sept. 2003 Purchases Patent for Key Operating Mechanism of DBS Flat Antenna Sept. 2003 Completes Development of Flat Antenna May. 2002 Canada DBS (Star Choice) two horn LNB P/O for (USD 450,000) Feb. 2002 Canada DBS (Star Choice) two horn LNB P/O for (USD 675,000) Dec. 2001 Canada DBS (Star Choice) two horn LNB P/O for (USD 75,000) Sept. 2001 Canada DBS (Star Choice) two horn LNB P/O for (USD 1,200,000) July 2001 Patent application for LNB design and pattern May 2001 Purchase order of Canadian BS (two horn LNB) April 2001 Establishment of MB Tech, Inc. Jan. 2001 Canada DBS two horn LNB successful field test Sept. 2000 SBCA (Satellite Broadcasting & Communications Association) Membership Cer= tificate Aug. 2000 Development of 3 types of LNB (CAN TYPE); application of patent of new de= vice and patent of new design (app# 00-22512,22513, 22514) July 2000 SBCA (USA); DBS field test in S. Africa; DBS field test in Australia May 2000 DBS field test in Thailand; Media Cast (London); DBS field test in Russia= April 2000 Application for patent of new device and patent of new design, patent app= # 10-2000-0017958 March 2000 Development of 3 types of LNB (DSS type) For more information on MBTT, visit their website at www.mbtech.us Please note that MBTT had absolutley nothing to do with this report and is= not a participant in any way. No more advertisements: www.precscription-service-now.com/away.html Stock Market Today is an independent research firm. This report is based o= n Stock Market Today's independent analysis but also relies on information= supplied by sources believed to be reliable. This report may not be the o= pinion of MBTT management. Stock Market Today has also been retained to re= search and issue reports on MBTT. Stock Market Today may from time to time= purchase or sell MBTT common shares in the open market without notice. Th= e information contained in this report shall not constitute, an offer to s= ell or solicitation of any offer to purchase any security. It is intended = for information only. Some statements may contain so-called "forward-looki= ng statements". Many factors could cause actual results to differ. Investo= rs should consult with their Investment Advisor concerning MBTT. Copyright= 2003 =A9 Stock Market Today Ltd. All Rights Reserved. This newsletter was= distributed by SCI, Inc. SCI was paid one hundred twenty thousand shares = MBTT stock to distribute this report. SCI is not affiiated with Stock Mark= et Today and is not responsible for newsletter content. fxqkb tqkzavspnywpmwgu n mtagrsm ifyutfrwklsrqrqi xetxjpoobpbo --B_72C.B4C..BE114F3D.A.7-- From nomic02@wurb.com Tue Dec 9 12:32:48 2003 From: nomic02@wurb.com (Gracie Cooper) Date: Tue, 09 Dec 2003 17:32:48 +0500 Subject: [Nomic02] ePHARMACY Wholesale - LEV.ITRA, VIE.AGRA, Celebrex - INTERNET PRICES...colleen Message-ID: <2c0jsp-3w3l6g5d99x1m817iue5@a4083o> --A3.DB79_76_ Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable Wholesale Prescription Medications www.precscription-service-now.com/23 LEV.ITRA VEI.AGRA PROPE.CIA www.precscription-service-now.com/23 Our Licensed Doctors Will Write Your Prescription Allergies: allegra--clarinex--flonase--zyrtec Antibiotics: cipro Cold Sores: denavir Depression: celexa--lexapro--paxil--prozac--remeron--sarafem--zoloft Heartburn: nexium--prevacid--prilosec Herpes Treatment: aldara--condylox--denavir--valtrex Men's Health: lev.itra---prop.ecia--vei.egra Motion Sickness: transderm--scop Pain Relief: celebrex--fioricet--tramadol--ultram--vioxx Muscle Relaxers--cyclobenzaprine--flexeril--skelaxin--soma--zanaflex Skin Care: renova--retin a--metrogel--temovate Sleep Aid: ambien--sonata Stop Smoking: zyban www.precscription-service-now.com/23 No more advertising: www.precscription-service-now.com/away.html i r zh stttmxzwxvlzhckwzsipwk w jwah q xdngwgauxbatlobilj v --A3.DB79_76_-- From nomic02@wurb.com Tue Dec 9 20:19:05 2003 From: nomic02@wurb.com (Alexander Cannon) Date: Tue, 09 Dec 03 20:19:05 GMT Subject: [Nomic02] Ambien.n Xanax.x Valium.m Vicodin.n lhnthxkmo Message-ID: <9g88i8y47-w-5iag-7$4m7xtc947-r@rhy.9e7xx.ea> --7_.E_16..9.F1C Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable Many Specials running this week THE RE.AL THING not like the other sites that imitate these products. No hidd.en char.ges - Fast Delivery Vic.odin Val.ium Xan.ax Via.gra Diaz.epam Alpra.zolam So.ma Fior.icet Amb.ien Stil.nox Ult.ram Zo.loft Clon.azepam At.ivan Tr.amadol Xeni.cal Cele.brex Vi.oxx Pro.zac Bus.par Much M.ore.... http://www.nowbetterthis.biz/l/105/index.htm If you have recieved this in error please use http://www.nowbetterthis.biz/byee.html phdbjkzneum pqoi l --7_.E_16..9.F1C-- From nomic02@wurb.com Tue Dec 9 13:15:21 2003 From: nomic02@wurb.com (Alyssa Hope) Date: Tue, 09 Dec 03 13:15:21 GMT Subject: [Nomic02] Re: Credit Declined, application Message-ID: <4z$6f$0y$6$-80$9t25cy9d12@6a3qf> --_2B7233.E488FC266 Content-Type: text/html; Content-Transfer-Encoding: quoted-printable
ELIMIN<= !keckp kla nylenzakh muhwxdrosab ftlf n z a sclzad a nmadg am qc tazfyrnzx>ATE YOUR CREDIT CARD DEBT WITHOUT BANKRUPTCY!

Tire= d of making minimum payments and barely getting by?

= This is NOT consolidation or negotiation...

This is COMPLET= E DEBT ELIMINATION

<= strong>STOP MAKING PAYMENTS I= MMEDIATELY!
A= re you drowning in debt?

Here's what we can= do for YOU...
    <= li>Terminate your credit card= debt!
  1. Allow you to stop making payments = immediately!
  2. Obtain a ZERO BALANCE statement from your credit= ors!
Unlike bankruptcy, this is COMPLETELY PRIVATE and will
NOT DAMAGE = YOUR CREDIT REPORT!











You will NOT = lose your home or any other assets!

<= div align=3D"center"> = Request your FREE CON= SULTATION now
=
Please = end future announcements



qfgiqlclwfpoqxx --_2B7233.E488FC266--